No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
100 µg brimonidine tartrate implant |
Brimonidine |
D02076, D07540 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 90 |
2 |
200 µg brimonidine tartrate implant |
Brimonidine |
D02076, D07540 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 90 |
3 |
400 µg brimonidine tartrate implant |
Brimonidine |
D02076, D07540 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 90 |
4 |
9715x |
- |
- |
- |
- |
1件: 90 |
5 |
9741x |
- |
- |
- |
- |
1件: 90 |
6 |
9742x |
- |
- |
- |
- |
1件: 90 |
7 |
Aav2/5-hpde6b |
- |
- |
- |
- |
1件: 90 |
8 |
Aav2/5-hrkp.rpgr |
- |
- |
- |
- |
1件: 90 |
9 |
Aav8-rpgr |
- |
- |
- |
- |
1件: 90 |
10 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
11 |
Acetazolamide |
Acetazolamide |
D00218, D01196 |
13件: CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
7件: Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
6件: 13, 90, 115, 155, 225, 230 |
12 |
Aflibercept |
Aflibercept |
D09574 |
3件: PGF, VEGFA, VEGFB |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
2件: 90, 166 |
13 |
Alga dunaliella bardawil |
- |
- |
- |
- |
1件: 90 |
14 |
Alga dunaliella bardawil powder |
- |
- |
- |
- |
1件: 90 |
15 |
Alga dunaliella bardawill |
- |
- |
- |
- |
1件: 90 |
16 |
Amino acids |
Amino acids |
- |
- |
- |
4件: 70, 90, 240, 298 |
17 |
Antioxidants |
- |
- |
- |
- |
4件: 90, 298, 301, 310 |
18 |
Betamethasone |
Betamethasone |
D00244, D00972, D01357, D01402, D01637, D02032, D02286 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
6件: 2, 46, 65, 90, 96, 235 |
19 |
Bmmncs |
- |
- |
- |
- |
1件: 90 |
20 |
Brimonidine |
Brimonidine |
D02076, D07540 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 90 |
21 |
Brimonidine tartrate |
Brimonidine |
D02076, D07540 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 90 |
22 |
Brimonidine tartrate posterior segment drug delivery system (brimo ps dds) applicator system |
Brimonidine |
D02076, D07540 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 90 |
23 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
24 |
Carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
25 |
Cd34+ bone marrow stem cells intravitreal |
- |
- |
- |
- |
1件: 90 |
26 |
Cholesterol |
Cholesterol |
D00040 |
- |
- |
7件: 19, 90, 160, 259, 261, 301, 310 |
27 |
Ciliary neurotrophic factor |
Ciliary neurotrophic factor |
- |
- |
- |
1件: 90 |
28 |
Ciliary neurotrophic factor implant nt-501 |
Ciliary neurotrophic factor |
- |
- |
- |
1件: 90 |
29 |
Circadin 2 mg |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 90 |
30 |
Circadin 2 mg comprimidos de liberación prolongada |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 90 |
31 |
Cnto 2476 |
- |
- |
- |
- |
1件: 90 |
32 |
Compound thrombosis capsule sig: 1.5g/tid |
- |
- |
- |
- |
1件: 90 |
33 |
Continuous oxygen |
Oxygen |
D00003 |
- |
- |
1件: 90 |
34 |
Coqun |
- |
- |
- |
- |
1件: 90 |
35 |
Cornstarch control |
- |
- |
- |
- |
1件: 90 |
36 |
Cpk850 |
- |
- |
- |
- |
1件: 90 |
37 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
38 |
Cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
39 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
40 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
41 |
Dorzolamide |
Dorzolamide |
D00653, D07871 |
13件: CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
7件: Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
1件: 90 |
42 |
Eylea |
Aflibercept |
D09574 |
3件: PGF, VEGFA, VEGFB |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
2件: 90, 166 |
43 |
Fluocinolone |
Fluocinolone |
- |
- |
- |
1件: 90 |
44 |
Fluocinolone acetonide |
Fluocinolone acetonide |
D01825 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 90 |
45 |
Ginkgo |
Ginkgo biloba |
- |
- |
- |
3件: 6, 13, 90 |
46 |
Ginkgo biloba |
Ginkgo biloba |
- |
- |
- |
2件: 13, 90 |
47 |
Ginkgo biloba pills sig: 300mg/tid |
Ginkgo biloba |
- |
- |
- |
1件: 90 |
48 |
Hora-pde6b (aav2/5.hpde6b) |
- |
- |
- |
- |
1件: 90 |
49 |
Hrpc |
- |
- |
- |
- |
1件: 90 |
50 |
Human embryonic stem cell derived retinal pigment epithelium (rpe) |
- |
- |
- |
- |
1件: 90 |
51 |
Human primary retinal pigment epithelial (hurpe) cells |
- |
- |
- |
- |
1件: 90 |
52 |
Human retinal progenitor cells |
- |
- |
- |
- |
1件: 90 |
53 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
54 |
Hydroxychloroquine higher dose |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 90 |
55 |
Hydroxychloroquine lower dose |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 90 |
56 |
Iluvien |
Fluocinolone acetonide |
D01825 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 90 |
57 |
Interferon gamma-1b |
- |
- |
- |
- |
7件: 65, 85, 90, 228, 299, 301, 326 |
58 |
Intravitreal injection of autologous bone marrow stem cell |
- |
- |
- |
- |
1件: 90 |
59 |
Intravitreal injection of autologous bone marrow stem cells |
- |
- |
- |
- |
1件: 90 |
60 |
Levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
7件: 2, 4, 6, 17, 90, 164, 201 |
61 |
Levodopa-carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
2件: 6, 90 |
62 |
Lutein |
Lutein |
- |
- |
- |
2件: 90, 164 |
63 |
Lutein (10 or 30 mg/day) capsules |
Lutein |
- |
- |
- |
1件: 90 |
64 |
Lycium barbarum |
- |
- |
- |
- |
1件: 90 |
65 |
Melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
66 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
67 |
N-acetyl cysteine (nac) |
L-cysteine |
D00026, D02326 |
- |
- |
1件: 90 |
68 |
Nac effervescent tablets |
- |
- |
- |
- |
1件: 90 |
69 |
Nerve growt factor - 2.5s |
- |
- |
- |
- |
1件: 90 |
70 |
Nerve growth factor |
Nerve growth factor |
- |
- |
- |
2件: 3, 90 |
71 |
Nilvadipine |
Nilvadipine |
D01908 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 90 |
72 |
Nt-501 |
- |
- |
- |
- |
2件: 90, 303 |
73 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
74 |
Nutritional supplement |
- |
- |
- |
- |
1件: 90 |
75 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
76 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
77 |
Qlt091001 |
- |
- |
- |
- |
1件: 90 |
78 |
Qr-1123 |
- |
- |
- |
- |
1件: 90 |
79 |
Qr-421a |
- |
- |
- |
- |
2件: 90, 303 |
80 |
Raav2tyf-grk1-rpgr |
- |
- |
- |
- |
1件: 90 |
81 |
Recombinant human nerve growth factor (rhngf) |
Nerve growth factor |
- |
- |
- |
1件: 90 |
82 |
Retinal pigment epitheliums transplantation |
- |
- |
- |
- |
1件: 90 |
83 |
Rhngf |
Cenegermin |
D11028 |
1件: NGFR |
8件: Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer |
1件: 90 |
84 |
Rhngf 180 µg/ml eye drops solution |
Cenegermin |
D11028 |
1件: NGFR |
8件: Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer |
1件: 90 |
85 |
Rhngf 60 µg/ml eye drops solution |
Cenegermin |
D11028 |
1件: NGFR |
8件: Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer |
1件: 90 |
86 |
Rst-001 |
- |
- |
- |
- |
1件: 90 |
87 |
Sodium valproate |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
4件: 2, 90, 102, 256 |
88 |
Stem cell transplantation |
- |
- |
- |
- |
9件: 13, 19, 20, 46, 65, 90, 164, 234, 326 |
89 |
Stem/progenitor cells transplantation |
- |
- |
- |
- |
2件: 90, 301 |
90 |
Tocoferol |
Tocopherol |
D02332 |
- |
- |
1件: 90 |
91 |
Triamcinolone |
Triamcinolone |
D00385, D00983, D00984, D00985, D06216 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 35, 46, 56, 70, 90, 96, 226, 298 |
92 |
Twice-daily dosage with 0.5% cyclosporine-a eyedrops |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 90 |
93 |
Uf-021 |
- |
- |
- |
- |
1件: 90 |
94 |
Uf-021 (isopropyl unoprostone) |
Unoprostone |
D08661 |
1件: PTGFR |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway |
1件: 90 |
95 |
Uf-021(isopropyl unoprostone) |
Unoprostone |
D08661 |
1件: PTGFR |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway |
1件: 90 |
96 |
Unoprostone |
Unoprostone |
D08661 |
1件: PTGFR |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway |
1件: 90 |
97 |
Valproate |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
6件: 2, 3, 90, 102, 233, 256 |
98 |
Valproic acid |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
10件: 3, 5, 26, 34, 65, 89, 90, 222, 256, 331 |
99 |
Vehicle eye drops |
- |
- |
- |
- |
1件: 90 |
100 |
Vitamin a |
Vitamin a |
D00069, D06543 |
2件: RARA, RARB |
8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
3件: 13, 53, 90 |
101 |
Vitamin ad sig: 1 tablet/tid |
- |
- |
- |
- |
1件: 90 |
102 |
Vitamin b sig: 10mg/tid |
- |
- |
- |
- |
1件: 90 |
103 |
Vitamin e |
Vitamin e |
D02331 |
- |
- |
11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
104 |
Zuretinol acetate |
Zuretinol acetate |
- |
- |
- |
1件: 90 |